GSK, Novartis, Lilly play musical chairs

GSK, Novartis, Lilly play musical chairs


The three drugmakers rearranged part of the pharma universe Tuesday with a string of pipeline-altering deals.

Valeant bids $47B for Allergan

Valeant bids $47B for Allergan


The deal would bring Allergan's Botox and Juvederm under the same roof as Restylane.

Rumor: Pfizer offered to buy AstraZeneca

The rumored $101 billion bid would give Pfizer a foothold in imuno-oncology and diabetes.

Roche seals two deals in one weekend

The Swiss drugmaker has scooped up Oryzon's experimental acute myeloid leukemia treatment and private Massachusetts diagnostics firm IQuum.

Forest acquisition whets M&A appetite

Bloomberg reports that Teva has sparked interest as a takeover target.

Actavis buys Forest, bolsters specialty biz

Actavis buys Forest, bolsters specialty biz


The drugmaker, hitherto known for its generic expertise, says the purchase could mean that half its future revenue will come from branded, specialty drugs.

Novartis expands immuno-oncology presence

Novartis expands immuno-oncology presence


The drugmaker's purchase of private biotech CoStim Pharmaceuticals comes with a host of experimental immuno-oncology agents.

Merck, Genzyme, Alnylam play RNA musical chairs

The three drugmakers launched into a series of sell-offs and acquisitions over the weekend.

Merck and Novartis rumored to swap assets

An insider says Merck may be up for trading its OTC business for Novartis's animal health business, but the benefits for either side may be better on paper.

AstraZeneca buys CDK9 portfolio

The company purchased assets from Germany-based Probiodrug.

GE buys interest in DNA

The finance, electric and broadcasting company has taken a $1-billion interest in DNA technology.

Bayer buys Algeta

The $2.9 billion deal means Bayer owns prostate cancer drug Xofigo in full.

Forest, Eisai announce slim-downs

Forest's cost-savings initiative is aimed at reducing operating expenses by $500 million, while Eisai said it's cutting 130 positions in the US and Europe.

Shire, Salix buy way to expansion

The companies are plunking down substantial sums to increase their reach.

Endo swallows Paladin for $1.6B

The "New Endo" will be one company on the outside, two on the inside.

Report: Dendreon looking for buyer

The prostate cancer drug company is reportedly seeking a buyer to turn things around.

One day, two AstraZeneca deals

The drug maker is beefing up its MedImmune offerings with a $440-million acquisition and a deal with ADC Therapeutics.

Business briefs: Takeda, Sangamo, Catalyst, plus seniors and insurance

Takeda moves an Alzheimer's treatment to Phase III; Sangamo acquires Ceregene; Catalyst gets breakthrough designation for auto-immune disorder drug; study says seniors likely to opt out of health insurance

Business briefs: Akorn, Bayer, Lonza, plus curbing CNS drug use

Akorn expands, buying Hi-Tech Pharmacal; nursing homes miss their goal to curb antipsychotic-drug use; Bayer cancer drug gets priority review; and Lonza lays off staff

Kyprolis growth prospects at center of Amgen-Onyx deal

Kyprolis growth prospects at center of Amgen-Onyx deal


Amgen's newest oncology asset could reach great heights, if the firm can capitalize on its existing commercial and R&D capabilities.

AstraZeneca reinforces oncology push

AstraZeneca reinforces oncology push


The drug maker is adding Amplimunne's cancer portfolio to subsidiary MedImmune's oncology efforts, one of several recent deals to add heft.

Business briefs: Novartis, Regeneron and Pfizer

Novartis prepares for a strategic review that hints at scuttling lesser-performing businesses; Regeneron's Eylea sales prompt expansion; Pfizer targets diabetes and obesity; and the FDA approves an MS stem cell trial

Business briefs: Medtronic, Novo Nordisk, plus OIG's latest probe

Medtronic buys up Cardiocom, Novo will file liraglutide to battle obesity, HHS navigates cutback and looks into anti-psychotic prescription rates, Amgen's Neulasta to compete against Teva's Lonquex.

Merck buys controlling stake in Physicians Interactive


The drug maker, through its venture fund, took a controlling interest in the digital physician marketing firm.

Cubist buying spree bolsters antibiotic roster


The drug maker added biotechs Optimer and Trius to the fold, a bid to dominate in hard-to-treat infections.

Business briefs: Elan and Valeant

Perrigo sweeps Elan off its feet for $8.6 billion, and Valeant is slashing 2,700 jobs.

Business briefs: Onyx, Pfizer, Covidien

Onyx says no to Amgen bid, yes to other options; Pfizer/BMS may be able to expand Eliquis appeal; Covidien officially divides into two.

Business briefs: GSK and Sanofi, plus state legislative news

GlaxoSmithKline says it is scaling back on acquisitions; Sanofi's CEO picks a regulatory fight; Maine wants to allow Ex-US meds; and New York State seeks to empower pharmacists.

J&J expands pipeline in prostate cancer


The pharmaceutical behemoth is betting at least $650 million on the Aragon Pharmaceuticals Ph. II drug.

AstraZeneca buys respiratory specialist Pearl Therapeutics


The drug maker eases the burden on its Symbicort franchise by scooping up Pearl for $510 million.

Email Newsletters